Mental Health Rewritten
Dosed Wellness is uniquely positioned as an early mover in the psychedelics space with a network of physicians and clinics, advanced research opportunities, telehealth capabilities, and a growing base of over 165,000 patients.
WHY IS THIS IMPORTANT?
people suffer from mental illness and addiction
projected global market for mental health/neurological disorders by 2025
people currently suffering from inadequate first-line treatment options
We break down the stigma surrounding psychedelics for the treatment of mental illness by researching, developing, and deploying psychedelic inspired medicines to support mental wellness.
After years of red tape, progress is finally being made towards fully researching the medicinal effects of a unique class of pharmacological compounds known as psychedelics for use in treating conditions like depression, anxiety, PTSD, addiction, and much more. We want to partner with research institutions to move the science forward by leveraging our clinic network and direct access to patients.
WHAT IF THERE WAS A BETTER WAY?
Early studies suggest that psilocybin (the psychotropic compound in magic mushrooms) is very effective in the treatment of mental illness, PTSD and addiction, with therapeutic benefits that appear to be fast-working, non-addictive and side-effect-free. It is our belief, and research tends to agree, that ‘psychedelic’ treatments, managed within a therapeutic environment, will have a profound global impact on humanity’s health through the treatment of depression, addiction, PTSD, anxiety, addiction, and other mental health issues. That’s why we are working with researchers to develop groundbreaking medicines to transform the way our world treats mental illness.
Our team of experts has been treating conditions like anxiety, depression, PTSD, and more for years utilizing CBD and various plant-based treatment options. For us, the transition to psilocybin and other psychedelics is the next step in revolutionizing mental wellness care.
Early research, along with promising outcomes across many indications and disorders, has garnered the attention of and changed the perceptions held by the medical, regulatory and investment communities. Recently, a wave of decriminalization of psilocybin and other psychedelics is sweeping across the US (Denver, Oakland and Santa Cruz) and in countries such as Brazil, Netherlands, Jamaica and Peru.
Looking at the market, competition is limited with few public offerings, operating alongside small-to-medium sized companies that have been privately funded by entrepreneurs and venture capital firms. That will soon change and Dosed Wellness is poised to lead the charge.